Antibody-drug conjugates specific for CD276 and uses thereof

An improved antibody-drug conjugate (ADC) targeting CD276-positive tumors is described. The ADC includes a CD276-specific IgG1 antibody having a heavy chain modified to prevent interaction of its Fc domain with endogenous Fc receptors and to introduce a cysteine for site-specific conjugation of the...

Full description

Saved in:
Bibliographic Details
Main Authors FENG, Yang, SEAMAN, Steven, ST. CROIX, Brad
Format Patent
LanguageEnglish
Published 30.06.2022
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:An improved antibody-drug conjugate (ADC) targeting CD276-positive tumors is described. The ADC includes a CD276-specific IgG1 antibody having a heavy chain modified to prevent interaction of its Fc domain with endogenous Fc receptors and to introduce a cysteine for site-specific conjugation of the drug. The CD276-specific ADC is capable of potently eradicating CD276-positive tumors in several animal models.
Bibliography:Application Number: AU20200402752